Diasome Pharmaceuticals: A Future Without Lows?

Recently, Diasome Pharmaceuticals announced positive results from its Phase 2 OPTI-1 study on the efficacy of its hepatocyte directed vesicle (HDV) technology for preventing low blood sugar in patients with type 1 diabetes. The study results showed that this liver-targeted insulin may allow patients to reduce the amount of time they spend in hypoglycemia by […]